A targeted mouse Brca1 mutation removing the last BRCT repeat results in apoptosis and embryonic lethality at the headfold stage

被引:49
作者
Hohenstein, P
Kielman, MF
Breukel, C
Bennett, LM
Wiseman, R
Krimpenfort, P
Cornelisse, G
van Ommen, GJ
Devilee, P
Fodde, R
机构
[1] Leiden Univ, Med Ctr, Dept Human & Clin Genet, NL-2300 RA Leiden, Netherlands
[2] Leiden Univ, Med Ctr, Dept Pathol, NL-2300 RA Leiden, Netherlands
[3] NIEHS, Res Triangle Pk, NC 27709 USA
[4] Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands
关键词
Brca1(1700T); mouse model; hereditary breast cancer; p53; genotype-phenotype correlation; DNA damage;
D O I
10.1038/sj.onc.1204363
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A mouse model with a targeted mutation in the 3' end of the endogenous Brca1 gene, Brca1(1700T), was generated to compare the phenotypic consequences of truncated SI cal proteins with other mutant Brca1 models reported in the literature to date. Mice heterozygous for the Brca1(1700T) mutation do not show any predisposition to tumorigenesis, Treatment of these mice with ionizing radiation or breeding with Ape, Msh-2 or Tp53 mutant mouse models did not show any change in the tumor phenotype, Like other Brca1 mouse models, the Brca1(1700T) mutation is embryonic lethal in homozygous state, However, homozygous Brca1(1700T) embryos reach the headfold stage but are delayed in their development and fail to turn. Thus, in contrast to Brca1(null) models, the mutant embryos do not undergo growth arrest leading to a developmental block at 6.5 dpc, but continue to proliferate and differentiate until 9.5 dpc. Homozygous embryos die between 9.5-10.5 dpc due to massive apoptosis throughout the embryo. These results indicate that a C-terminal truncating Brca1 mutation removing the last BRCT repeat has a different effect on normal cell function than does the complete absence of Brca1.
引用
收藏
页码:2544 / 2550
页数:7
相关论文
共 46 条
[1]  
BENNETT LM, 1995, GENOMICS, V29, P576, DOI 10.1006/geno.1995.9963
[2]  
Blaszyk H, 2000, INT J CANCER, V89, P32, DOI 10.1002/(SICI)1097-0215(20000120)89:1<32::AID-IJC6>3.0.CO
[3]  
2-G
[4]   A superfamily of conserved domains in DNA damage responsive cell cycle checkpoint proteins [J].
Bork, P ;
Hofmann, K ;
Bucher, P ;
Neuwald, AF ;
Altschul, SF ;
Koonin, EV .
FASEB JOURNAL, 1997, 11 (01) :68-76
[5]  
Chandler J, 2001, GENESIS, V29, P72, DOI 10.1002/1526-968X(200102)29:2<72::AID-GENE1007>3.0.CO
[6]  
2-B
[7]   Transcriptional activation by BRCA1 [J].
Chapman, MS ;
Verma, IM .
NATURE, 1996, 382 (6593) :678-679
[8]   Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells [J].
Chen, JJ ;
Silver, DP ;
Walpita, D ;
Cantor, SB ;
Gazdar, AF ;
Tomlinson, G ;
Couch, FJ ;
Weber, BL ;
Ashley, T ;
Livingston, DM ;
Scully, R .
MOLECULAR CELL, 1998, 2 (03) :317-328
[9]   A TARGETED CHAIN-TERMINATION MUTATION IN THE MOUSE APC GENE RESULTS IN MULTIPLE INTESTINAL TUMORS [J].
FODDE, R ;
EDELMANN, W ;
YANG, K ;
VANLEEUWEN, C ;
CARLSON, C ;
RENAULT, B ;
BREUKEL, C ;
ALT, E ;
LIPKIN, M ;
KHAN, PM ;
KUCHERLAPATI, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (19) :8969-8973
[10]   GERMLINE MUTATIONS OF THE BRCA1 GENE IN BREAST AND OVARIAN-CANCER FAMILIES PROVIDE EVIDENCE FOR A GENOTYPE-PHENOTYPE CORRELATION [J].
GAYTHER, SA ;
WARREN, W ;
MAZOYER, S ;
RUSSELL, PA ;
HARRINGTON, PA ;
CHIANO, M ;
SEAL, S ;
HAMOUDI, R ;
VANRENSBURG, EJ ;
DUNNING, AM ;
LOVE, R ;
EVANS, G ;
EASTON, D ;
CLAYTON, D ;
STRATTON, MR ;
PONDER, BAJ .
NATURE GENETICS, 1995, 11 (04) :428-433